FDA Section 361 Tissue Graft Procurement Guidelines

FDA Section 361 compliance guidelines govern Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) regulated solely under 21 CFR Part 1271 of the Code of Federal Regulations. To qualify under Section 361, human tissue grafts must be minimally manipulated, intended strictly for homologous use, and processed without systemic metabolic reliance or unauthorized handling agents. Medical practice administrators must verify that all tissue suppliers maintain active FDA registration, enforce Current Good Tissue Practice (cGTP), and provide comprehensive donor screening records before clinical integration.

Section 361 vs. Section 351: The Regulatory Landscape

Understanding the distinction between Section 361 and Section 351 of the Public Health Service (PHS) Act is essential for healthcare providers and procurement managers. The FDA categorizes allografts, cellular therapies, and tissue products into one of these two regulatory pathways based on risk, processing intensity, and clinical intent.

Section 361 HCT/Ps are regulated solely to prevent the introduction, transmission, and spread of communicable diseases. Because these products meet strict criteria regarding processing and clinical utility, they do not require premarket approval, clinical trial IND (Investigational New Drug) applications, or Biologics License Applications (BLAs). Tissue grafts falling under this category include structural birth tissues, amnion, bone allografts, and structural connective tissues.

In contrast, Section 351 products are classified as biologics or drugs. They require formal FDA approval prior to marketing, clinical trials demonstrating efficacy, and extensive premarket licensing. If an HCT/P fails to meet even one of the criteria under 21 CFR 1271.10, it automatically defaults to a Section 351 biologic regulation. Purchasing non-compliant tissue products exposes practices to significant legal, regulatory, and financial liabilities.

Core Criteria for Section 361 Compliance

To maintain eligibility under Section 361, a human tissue graft must satisfy four mandatory statutory criteria outlined in 21 CFR Part 1271:

1. Minimal Manipulation

For structural tissue, minimal manipulation means processing that does not alter the original relevant characteristics of the tissue relating to its utility for reconstruction, repair, or replacement. For non-structural tissue, it means processing that does not alter the relevant biological characteristics. Mechanical processing, rinsing, cutting, and cryopreservation typically satisfy this requirement, whereas enzymatic digestion or cellular expansion push a product into Section 351.

2. Homologous Use Only

Homologous use means the repair, reconstruction, replacement, or supplementation of a recipient's cells or tissues with an HCT/P that performs the same basic function in the recipient as in the donor. Tissue grafts marketed or applied for non-homologous uses—such as injecting structural connective tissue for systemic diseases—violate Section 361 guidelines.

3. Non-Combination with Other Articles

The tissue product must not be combined with another drug, device, or synthetic agent, with limited exceptions (such as approved water, crystalloids, or sterilizing agents that do not alter the biological effect of the graft).

4. Dependent on Local Structural Action

The HCT/P must not rely on the metabolic function or systemic activity of living cells to achieve its primary function, unless it is for autologous use, allogeneic use in first-degree or second-degree blood relatives, or reproductive use.

Practice administrators evaluating biologics must ensure that manufacturer processing documentation explicitly supports all four criteria.

Operational Procurement Checklist for Practice Managers

When procuring human tissue grafts, practice managers bear primary responsibility for establishing vendor qualification protocols. Every supplier must be audited against key regulatory checkpoints before clinical inventory is received.

Use the following checklist during vendor evaluation:

• FDA Registration Status: Verify that the tissue processing facility holds an active FDA Establishment Registration (FDA Form 3356) listed in the FDA Human Cell and Tissue Establishment Registration (eHERC) database.
• Donor Screening Protocols: Confirm that donor eligibility determinations strictly follow 21 CFR 1271 Subpart C, including comprehensive medical history reviews, physical assessments, and infectious disease testing.
• CLIA-Certified Testing: Ensure testing for communicable diseases (HIV-1/2, Hepatitis B, Hepatitis C, Syphilis, HTLV I/II, and West Nile Virus) is performed by a CLIA-certified laboratory using FDA-licensed donor screening test kits.
• cGTP Compliance Documentation: Request documentation demonstrating adherence to Current Good Tissue Practice regulations (21 CFR Part 1271 Subpart D), covering facility sanitation, environmental controls, equipment calibration, and process validation.
• Chain of Custody and Traceability: Inspect product labeling to verify unique donor identifiers, lot numbers, expiration dates, and tissue recovery tracking systems that comply with FDA requirements for end-to-end traceability.
• Storage and Cold Chain Handling: Validate temperature logging procedures, shipping containers, and local storage requirements (e.g., ambient vs. cryogenic storage) to protect tissue integrity prior to application.

Clinical Perspective: Translating Compliance to Bedside Care

For regenerative medicine doctors and clinical specialists, regulatory compliance directly correlates with patient safety and treatment reliability. While practice administrators manage vendor verification, treating physicians remain accountable for clinical decision-making and patient outcomes.

Clinicians must ensure that the rationale for applying a tissue graft aligns with its documented homologous function. For example, using an amniotic or chorionic tissue graft as a protective covering or barrier in soft tissue defects reflects homologous structural application. Documenting the clinical rationale in the patient's medical record protects both patient welfare and practice integrity.

Furthermore, physicians should participate in adverse event monitoring. Under 21 CFR Part 1271.350, tissue establishments must investigate and report any adverse reaction involving communicable disease transmission or product contamination. Practices must maintain internal standard operating procedures (SOPs) for reporting unexpected post-procedure events to both the distributor and the FDA.

Operational Risk Management and Chain of Custody

Establishing robust internal procurement workflows minimizes regulatory risk. When a shipment arrives at the practice, clinical staff should verify package integrity, inspect tamper-evident seals, and cross-reference the enclosed donor tissue passport with the order invoice.

Log all incoming tissue into an internal inventory management system that captures:

1. Tissue identification code and unique donor lot number
2. Expiration date and storage location
3. Date received and receiver signatures
4. Storage temperature confirmation at intake

Upon clinical use, the specific tissue lot number must be scanned or written directly into the patient's electronic health record (EHR) alongside the anatomical site of application. This creates an uninterrupted chain of custody from donor recovery through final administration.

What This Means for Your Practice

Adhering to FDA Section 361 compliance guidelines is an ongoing operational commitment rather than a one-time audit. Non-compliance by a tissue manufacturer can lead to FDA warning letters, product recalls, or practice liability if non-compliant biologics are administered.

To safeguard your practice:

• Conduct annual audits of all biological tissue suppliers.
• Review supplier regulatory standing in the FDA database every 6 to 12 months.
• Standardize clinic SOPs for intake, temperature logging, and EHR patient mapping.
• Provide staff training on handling biological products and identifying structural vs. non-structural classifications.

Practices interested in learning more about compliant device and tissue integration can consult Dallas Regenerative Solutions to evaluate their procurement workflows.

Partnering for Compliant Biologics Sourcing

Navigating FDA Section 361 compliance guidelines requires a knowledgeable procurement partner committed to transparency, donor safety, and regulatory compliance. Dallas Regenerative Solutions works with licensed healthcare providers to deliver fully compliant biological tissue products, high-power lasers, and advanced medical equipment.

For more details on compliance standards, tissue procurement protocols, or practice integration support, explore our FAQ page or contact our team for a tailored consultation.